RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIe

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02255435

Recruitment Status : Active, not recruiting

First Posted : October 2, 2014

Last Update Posted : March 4, 2019

Sponsor:

Collaborators:

AbbVie

Friedreich's Ataxia Research Alliance

Information provided by (Responsible Party):

Reata Pharmaceuticals, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	January 2020
Estimated Study Completion Date :	December 2022

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Lynch DR, Farmer J, Hauser L, Blair IA, Wang QQ, Mesaros C, Snyder N, Boesch S, Chin M, Delatycki MB, Giunti P, Goldsberry A, Hoyle C, McBride MG, Nachbauer W, O'Grady M, Perlman S, Subramony SH, Wilmot GR, Zesiewicz T, Meyer C. Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia. Ann Clin Transl Neurol. 2018 Nov 10;6(1):15-26. doi: 10.1002/acn3.660. eCollection 2019 Jan.

To Top